Abstracts tagged "Clinical practice"

Abstract Number: 2348 • 2018 ACR/ARHP Annual Meeting
Prescriber Attitudes and Beliefs about Triple Therapy for Patients with Rheumatoid Arthritis: Knowledge Exchange in Internet Forums and Social Media
Maria A. Lopez-Olivo¹, Jude K. A. des Bordes¹, Gregory Pratt² and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: Several forums on the internet serve as repositories of personal experiences and exchange of health information. Online discussions among healthcare providers about management of…
Abstract Number: 2516 • 2018 ACR/ARHP Annual Meeting
Long-Term Maintenance of Response in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol
Alain Saraux¹, René-Marc Flipo², Francis Fagnani³, Gabrielle Cukierman⁴, Isabelle Bru⁴, Jean-Michel Joubert⁴, Jan-Christof Schuller⁵, Jacques Massol⁶ and Bernard Combe⁷, ¹CHU La Cavale Blanche, Brest, France, ²Hôpital Roger Salengro, Lille, France, ³Cemka-Eval, Bourg-la-Reine, France, ⁴UCB Pharma, Colombes, France, ⁵UCB Pharma, Brussels, Belgium, ⁶CHU de Besançon, Besançon, France, ⁷CHU Lapeyronie, Montpellier, France
Background/Purpose: The safety and efficacy of certolizumab pegol (CZP) for treating patients (pts) with rheumatoid arthritis (RA) are well-established in a clinical trial setting.1,2 However,…
Abstract Number: 2589 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics and Treatment Profile of Patients with Psoriatic Arthritis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Mei Liu², Sabrina Rebello³, Meghan Glynn², Peter Hur⁴ and Philip J. Mease⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ, ⁵Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Few real-world studies have characterized patients with psoriatic arthritis (PsA) who initiate secukinumab. This study described characteristics of patients who initiated secukinumab and other…
Abstract Number: 2609 • 2018 ACR/ARHP Annual Meeting
Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice
Dalifer Freites Núñez¹, Zulema Rosales Rosado^1,2, Judit Font Urgelles², Isabel Hernández-Rodríguez², Leticia Leon¹, Gloria Candelas Rodriguez², Luis Rodriguez-Rodriguez¹, Benjamín Fernández-Gutiérrez^1,2, Juan A Jover Jover² and Lydia A Alcazar¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that benefits from DMARDs, in this regard knowing more about these therapies is a great step…
Abstract Number: 2633 • 2018 ACR/ARHP Annual Meeting
Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE
Rebecca Heijke¹, Mathilda Björk¹, Martina Frodlund¹, Laura McDonald², Evo Alemao³ and Christopher Sjöwall¹, ¹Linköping University, Linköping, Sweden, ²Bristol-Myers Squibb, Uxbridge, United Kingdom, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Patient (pt)-reported outcome measures (PROMs) are important to inform shared decision-making between pts with SLE and physicians.1 Established measures of disease activity and organ…
Abstract Number: 2752 • 2018 ACR/ARHP Annual Meeting
Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 134 Patients of Clinical Practice
Monica Calderón Goercke¹, Javier Loricera², Diana Prieto Peña¹, Vicente Aldasoro³, Santos Castañeda⁴, Ignacio Villa-Blanco⁵, Alicia Humbría⁶, Clara Moriano Morales⁷, Susana Romero-Yuste⁸, Francisco Javier Narváez⁹, Catalina Gómez-Arango¹⁰, Eva Perez Pampín¹¹, Rafael Melero¹², Elena Becerra-Fernández¹³, Marcelino Revenga Martínez¹⁴, Noelia Álvarez-Rivas¹⁵, Carlos Galisteo¹⁶, Francisca Sivera¹⁷, Alejandro Olivé-Marqués¹⁸, Maria Concepcion Alvarez de Buergo¹⁹, Luisa Marena Rojas Vargas²⁰, Carlos Fernandez-Lopez²¹, Francisco Navarro²², Enrique Raya Álvarez²³, Eva Galindez-Agirregoikoa²⁴, Beatriz Arca²⁵, Roser Solans²⁶, Arantxa Conesa²⁷, Cristina Hidalgo-Calleja²⁸, Carlos Vázquez²⁹, Francisco Ortiz-Sanjuán³⁰, Pau Lluch³¹, Sara Manrique-Arija³², Paloma Vela³³, Eugenio De Miguel³⁴, Carmen Torres-Martín³⁵, Juan Carlos Nieto³⁶, Carmen Ordas-Calvo³⁷, Eva Salgado-Pérez³⁸, María Varela-García³⁹, Cristina Luna Gómez⁴⁰, Francisco J. Toyos Sáenz de Miera⁴¹, Nagore Fernandez-Llanio Cornella⁴², Jose Andrés Román Ivorra⁴³, Antonio García⁴⁴, Natalia Palmou-Fontana⁴⁵, Vanesa Calvo-Río⁴⁵, José Luis Martín-Varillas⁴⁵, Belén Atienza-Mateo⁴⁵, Carmen González-Vela⁴⁶, Alfonso Corrales⁴⁵, Elena Aurrecoechea⁴⁷, Raquel Dos Santos⁴⁸, Angel García-Manzanares¹³, Norberto Ortego Centeno⁴⁹, Sabela Fernández⁵⁰, Montserrat Corteguera³⁵, Miguel Angel González-Gay², José Luis Hernández² and Ricardo Blanco⁴⁵, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ⁴Rheumatology, Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, ⁵Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁶Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, ⁷Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, ⁸Hospital de Pontevedra. Spain, Pontevedra, Spain, ⁹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ¹⁰Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, ¹¹Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹²Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, ¹³Hospital Universitario de Torrevieja, Alicante. Spain, Alicante, Spain, ¹⁴Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, ¹⁵Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, ¹⁶Rheumatology, Hospital Parc-Taulí, Sabadell, Spain, ¹⁷Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, ¹⁸Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁹Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, ²⁰Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, ²¹Servicio de Reumatología, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña. España, A Coruña, Spain, ²²Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, ²³Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ²⁴Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, ²⁵Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, ²⁶Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ²⁷Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, ²⁸Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca. Spain, Salamanca, Spain, ²⁹Hospital Miguel Servet, Zaragoza. Spain, Zaragoza, Spain, ³⁰Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain, ³¹Rheumatology, Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, ³²Medicine, University of Málaga, MÁLAGA, Spain, ³³Reumatología, Hospital General Universitario Alicante, Alicante, Spain, ³⁴Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ³⁵Complejo Asistencial de Ávila, Ávila. Spain, Ávila, Spain, ³⁶Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³⁷Hospital Cabueñes, Gijón. Spain, Gijón, Spain, ³⁸Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense. Spain, Ourense, Spain, ³⁹Complejo Hospitalario de Navarra, Navarra, Spain, ⁴⁰Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, ⁴¹Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, ⁴²Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, ⁴³Hospital La Fe. Valencia. Spain, Valencia, Spain, ⁴⁴Hospital Unviersitario Virgen de las Nieves, Granada. Spain, Granada, Spain, ⁴⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴⁶Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴⁷Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁴⁸Complejo Hospitalario Universitario de Santiago. Spain, Santiago de Compostela, Spain, ⁴⁹Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁵⁰Rheumatology, Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain
Background/Purpose: Tocilizumab (TCZ) has showed efficacy in randomized clinical trials in Giant cell arteritis (GCA). Data were of selected patients including many GCA of recent…
Abstract Number: 2756 • 2018 ACR/ARHP Annual Meeting
A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatmet with Tocilizumab Compared with Giacta Trial
Monica Calderón Goercke¹, Javier Loricera², Diana Prieto Peña¹, Vicente Aldasoro³, Santos Castañeda⁴, Ignacio Villa-Blanco⁵, Alicia Humbría⁶, Clara Moriano Morales⁷, Susana Romero-Yuste⁸, Francisco Javier Narváez⁹, Catalina Gómez-Arango¹⁰, Eva Perez Pampín¹¹, Rafael Melero¹², Elena Becerra-Fernández¹³, Marcelino Revenga Martínez¹⁴, Noelia Álvarez-Rivas¹⁵, Carlos Galisteo¹⁶, Francisca Sivera¹⁷, Alejandro Olivé-Marqués¹⁸, Maria Concepcion Alvarez de Buergo¹⁹, Luisa Marena Rojas Vargas²⁰, Carlos Fernandez-Lopez²¹, Francisco Navarro²², Enrique Raya Álvarez²³, Eva Galindez-Agirregoikoa²⁴, Beatriz Arca²⁵, Roser Solans²⁶, Arantxa Conesa²⁷, Cristina Hidalgo-Calleja²⁸, Carlos Vázquez²⁹, Jose Andrés Román Ivorra³⁰, Pau Lluch³¹, Sara Manrique-Arija³², Paloma Vela³³, Eugenio De Miguel³⁴, Carmen Torres-Martín³⁵, Juan Carlos Nieto³⁶, Carmen Ordas-Calvo³⁷, Eva Salgado-Pérez³⁸, Cristina Luna Gómez³⁹, Francisco J. Toyos Sáenz de Miera⁴⁰, Nagore Fernandez-Llanio Cornella⁴¹, Antonio García⁴², Carmen Larena⁴³, Belén Atienza-Mateo⁴⁴, José Luis Martín-Varillas⁴⁴, Natalia Palmou-Fontana², Vanesa Calvo-Río⁴⁴, Carmen González-Vela⁴⁵, Alfonso Corrales⁴⁴, María Varela-García⁴⁶, Elena Aurrecoechea⁴⁷, Raquel Dos Santos⁴⁸, Angel García-Manzanares¹³, Norberto Ortego Centeno⁴⁹, Sabela Fernández⁵⁰, Francisco Ortiz-Sanjuán⁵¹, Montserrat Corteguera³⁵, Miguel Angel González-Gay², José Luis Hernández² and Ricardo Blanco⁴⁴, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ⁴Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ⁵Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁶Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, ⁷Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, ⁸Hospital Pontevedra. Pontevedra. Spain., Pontevedra, Spain, ⁹Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain, ¹⁰Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, ¹¹Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹²Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, ¹³Hospital Universitario de Torrevieja, Alicante. Spain, Alicante, Spain, ¹⁴Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, ¹⁵Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, ¹⁶Rheumatology, Hospital Parc-Taulí, Sabadell, Spain, ¹⁷Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, ¹⁸Hospital Trías i Pujol, Badalona, Barcelona, Spain, ¹⁹Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, ²⁰Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, ²¹Servicio de Reumatología, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña. España, A Coruña, Spain, ²²Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, ²³Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ²⁴Rheumatology, University Hospital of Basurto, Bilbao, Spain, ²⁵Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, ²⁶Systemic Autoimmune Diseases Unit, Hospital Vall d’Hebron, Barcelona, Barcelona, Spain, ²⁷Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, ²⁸Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca. Spain, Salamanca, Spain, ²⁹Hospital Miguel Servet, Zaragoza. Spain, Zaragoza, Spain, ³⁰Hospital La Fe. Valencia. Spain, Valencia, Spain, ³¹Rheumatology, Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, ³²UGC de Reumatología, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain., Málaga, Spain, ³³Reumatología, Hospital General Universitario Alicante, Alicante, Spain, ³⁴Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ³⁵Complejo Asistencial de Ávila, Ávila. Spain, Ávila, Spain, ³⁶Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³⁷Hospital Cabueñes, Gijón. Spain, Gijón, Spain, ³⁸Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense. Spain, Ourense, Spain, ³⁹Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, ⁴⁰Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, ⁴¹Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, ⁴²Hospital Unviersitario Virgen de las Nieves, Granada. Spain, Granada, Spain, ⁴³Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴⁶Complejo Hospitalario de Navarra, Navarra, Spain, ⁴⁷Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁴⁸Complejo Hospitalario Universitario de Santiago. Spain, Santiago de Compostela, Spain, ⁴⁹Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁵⁰Rheumatology, Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, ⁵¹Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain
Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…
Abstract Number: 2760 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
Sebastian H. Unizony¹, Jinglan Pei², Páris N. Sidiropoulos², Jennie H. Best², Christine Birchwood² and John H. Stone³, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Genentech, Inc., South San Francisco, CA, ³Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Previously, the GiACTA study demonstrated the superiority of subcutaneous (SC) tocilizumab (TCZ) plus prednisone vs prednisone alone in achieving sustained glucocorticoid (GC)-free remission in…
Abstract Number: 2774 • 2018 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Ischemic Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Judit Font Urgelles¹, Luis Rodriguez-Rodriguez², Zulema Rosales Rosado^1,2, Dalifer Freites Núñez², Leticia Leon², Inmaculada Morado¹, Esperanza Pato Cour¹, Juan A Jover Jover¹, Benjamín Fernández-Gutiérrez¹ and Lydia A Alcazar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: Clinical trials have shown the efficacy of Methotrexate (MTX) in giant cell arteritis (GCA) but it is necessary to corroborate these results in real…
Abstract Number: 2870 • 2018 ACR/ARHP Annual Meeting
Thresholds for Disease Activity Measures DAS28, CDAI, and RAPID3 Do Not Align with Clinical Practice Patterns of Rheumatoid Arthritis (RA) Disease Management Decisions
Brian C. Sauer¹, Chia-Chen Teng, MS¹, Neil A. Accortt², David H. Collier², Tzu-Chieh Lin² and Grant W. Cannon¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Treatment guidelines recommend using disease activity measures (DAMs) to guide RA therapy, but DAM use in real-world treatment decisions is not defined. We…
Abstract Number: 524 • 2018 ACR/ARHP Annual Meeting
Clinical Course of Interstitial Lung Disease in Rheumatoid Arthritis Patients in Clinical Practice
Cristina Vadillo Font¹, María A Nieto², Dalifer Freites Núñez³, Zulema Rosales Rosado^1,3, Leticia Leon³, Judit Font Urgelles¹, Juan A Jover Jover¹ and Lydia A Alcazar³, ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Chest diseases, Hospital Clínico San Carlos, Madrid, Spain, ³Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: Interstitial lung disease (ILD) is the extra-articular manifestation that most frequently worsens the course of Rheumatoid arthritis (RA) disease. Purpose: To describe the characteristics…
Abstract Number: 2872 • 2018 ACR/ARHP Annual Meeting
Variation in Predictors of Patient and Physician Defined Flares in Rheumatoid Arthritis
Anna O'Connor¹, Joshua Baker², Bryant R. England³, Brian C. Sauer⁴, Grant W. Cannon⁵ and J. Steuart Richards⁶, ¹Department of Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ³Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁶Pittsburgh VA Medical Center and University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The identification of risk factors associated with flares in RA is challenging because of the use of different composite disease activity scores and a…
Abstract Number: 1382 • 2017 ACR/ARHP Annual Meeting
Characteristics of Patients with Rheumatoid Arthritis and Atlanto-Axial Pannus
Jessica Williams¹, Andrew Joyce², Glenn Gaviola¹, Zacharia Isaac^1,2 and Joerg Ermann³, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, ³Harvard Medical School, Boston, MA
Background/Purpose: Formation of pannus, an inflammatory tissue mass, in the atlanto-axial joint of the cervical spine is an important sequela of rheumatoid arthritis (RA). Atlanto-axial…
Abstract Number: 1443 • 2017 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Dalifer Freites Núñez², Cristina Lajas Petisco¹, Esperanza Pato Cour¹, Leticia Leon², Judit Font Urgelles¹, Juan A Jover Jover¹ and Lydia A Alcazar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…
Abstract Number: 1460 • 2017 ACR/ARHP Annual Meeting
Predictive Factors Associated with Successful Down-Titration of Biologics for Rheumatoid Arthritis Patients in Clinical Practice
Takaaki Komiya¹, Kaoru Minegishi-Takase², Natsuki Sakurai¹, Yuichiro Sato¹, Hideto Nagai³, Naoki Hamada³, Yumiko Sugiyama³, Naomi Tsuchida¹, Yutaro Soejima³, Yosuke Kunishita³, Hiroto Nakano³, Daiga Kishimoto³, Koji Kobayashi², Reikou Kamiyama³, Ryusuke Yoshimi³, Yukiko Asami³, Yohei Kirino³, Shigeru Ohno⁴ and Hideaki Nakajima³, ¹Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ³Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁴Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Randomized clinical trials have shown that if a patient is in sustained remission, biological disease-modifying anti rheumatic drugs (bDMARDs) therapy can be tapered in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].